BRIEF published on 06/18/2025 at 07:05, 9 months 8 days ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 9 months 8 days ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 9 months 21 days ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 9 months 21 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 1 year ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 1 year ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 1 year 2 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 03/26/2026 at 21:00, 40 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 40 minutes ago Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours 20 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 8 hours 40 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 20:48, 52 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours 20 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 2 hours 30 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 3 hours 23 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 14 hours 10 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
